Market Challenges And Opportunities

Tourette Syndrome Treatment Market Drivers

Drug approvals by regulatory authorities is expected to boost the global tourette syndrome treatment market growth. For instance, in October 23, 2017, Neurocrine Biosciences Inc. announced that the Food Drug and Administration approved valbenazine orphan drug designation to treat the pediatric patients with the Tourette syndrome. Furthermore, in September 19, 2017, Teva Pharmaceutical Industries and Nuvelution Pharma announced their partnership to develop AUSTEDO (deutetrabenazine) tablets for the treatment of tics which is associated to tourette syndrome in pediatric patients in the U.S. This partnership will drive the development of Austedo (deutetrabenazine) in Tourette syndrome by bringing new treatment options more quickly which are more necessary for the affected young patients. These factors are expected to propel the global Tourette syndrome treatment market growth.

Moreover, there are several investigations made for the treatment of Tourette syndrome. For instance, in March 2019, Wesley Medical Research was partnering with the University of Sydney in Australia which carried the clinical trial to investigate whether the medical cannabis could be used to treat the individuals with Tourette syndrome. This trial will help examine efficacy and safety of cannabinoids on tic frequency as well as the psychiatric symptoms associated with Tourette syndrome.

Furthermore, the acquisitions of companies drive the growth of the Tourette syndrome treatment market. For instance, on August 14, 2018, Emalex Biosciences acquired the Psyadon Pharmaceuticals and the rights to develop, register and market ecopipam, the investigational drug of Psyadon Pharmaceuticals, which is used to treat the Tourette syndrome in children less than 16 years of age.

Tourette Syndrome Treatment Market Restraints

Withdrawal of the drugs in late stages of clinical trials has hampered the global Tourette syndrome treatment market growth. For instance, on December 12, 2018, Neurocrine Biosciences revealed that the phase IIb study of valbenazine did not meet the primary endpoint of reducing the tic severity in young people in moderate to severe form of diseases.